See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Elevidys sales weaken; Neumora gets into obesity

Summary by biopharmadive.com
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

1 Articles

biopharmadive.combiopharmadive.com
Center

Elevidys sales weaken; Neumora gets into obesity

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Friday, August 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Obesity icon

Obesity

News
For You
SearchBlindspotLocal